2-(methylamino)-N-[2-oxo-2-(2-oxopropylamino)ethyl]acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(methylamino)-N-[2-oxo-2-(2-oxopropylamino)ethyl]acetamide
• 化学式: C₈H₁₅N₃O₃
• 分子量: 201.22
• InChiKey: YBXLNHOGOZTTAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  87.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] PHOSPHOLIPID ETHER CONJUGATES AS CANCER-TARGETING DRUG VEHICLES<br/>[FR] CONJUGUÉS D'ÉTHER PHOSPHOLIPIDIQUE UTILISÉS EN TANT QUE VÉHICULES DE MÉDICAMENTS CIBLANT LE CANCER
  申请人：CELLECTAR BIOSCIENCES INC

  公开号：WO2021050917A1

  公开（公告）日：2021-03-18

  Disclosed herein are therapeutic compounds capable of targeting a broad range of tumor cells. The present disclosure is further directed to compositions comprising the therapeutic compounds, methods of manufacturing the therapeutic compounds, and methods of treating cancer comprising administering the therapeutic compounds.

  本文披露了能够针对广泛范围的肿瘤细胞的治疗化合物。本公开还涉及包含这些治疗化合物的组合物、制造这些治疗化合物的方法，以及包括给予这些治疗化合物的方法治疗癌症。
• Peptide compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10435445B2

  公开（公告）日：2019-10-08

  The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. (I) P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37- A38-A39-A40-P2 wherein each symbol is as defined herein.

  本发明提供了一种对 GIP 受体具有激活作用的新型多肽化合物以及该多肽化合物作为药物的用途。 具体而言，本发明提供了一种含有式（I）所代表序列的多肽或其盐，以及一种包含该多肽的药物。 (I) P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37- A38-A39-A40-P2 其中各符号如本文所定义。
• Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
  申请人：STC.UNM

  公开号：US10464985B2

  公开（公告）日：2019-11-05

  The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

  本发明涉及新型非侵入性诊断工具/化合物，用于对癌症，特别是黑色素瘤，包括转移性黑色素瘤进行体内成像。本发明化合物在癌细胞和组织中的吸收增强，在肾脏中的吸收降低，证明本发明化合物的药代动力学良好。本发明的化合物是利用非侵入性分子成像技术诊断和治疗黑色素瘤（包括转移性黑色素瘤）的一大进步。本发明的新型探针还可用于启动黑色素瘤的治疗，以及监测患者对化疗治疗和用于治疗黑色素瘤/转移性黑色素瘤的其他干预或疗法的反应。根据本发明的化合物可用作一些病症和疾病状态的诊断工具以及治疗这些病症和疾病状态的治疗剂。
• COMPOUNDS WITH REDUCED RING SIZE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME
  申请人：STC. UNM

  公开号：US20190106474A1

  公开（公告）日：2019-04-11

  The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
• PEPTIDE COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20200140505A1

  公开（公告）日：2020-05-07

  The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P 1 -Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P 2 (I) wherein each symbol is as defined herein.